Skip to main content
SupplementScience

SAMe (S-Adenosyl Methionine) Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Strong

SAMe has one of the strongest evidence bases among joint supplements, with multiple head-to-head trials against NSAIDs. The Soeken et al. (2002) meta-analysis of 11 RCTs conclusively showed SAMe was as effective as NSAIDs for OA pain while causing fewer side effects. Najm et al. (2004) confirmed equivalence with celecoxib at 16 weeks, though SAMe had a slower 4-week onset. The Agency for Healthcare Research and Quality (AHRQ) reviewed the evidence and concluded SAMe is effective for OA pain. Mechanistically, SAMe offers both symptomatic and potential disease-modifying benefits through its role in cartilage metabolism — it stimulates proteoglycan synthesis by donating methyl groups essential for chondrocyte function.

Evidence by Condition

ConditionStudied DoseEvidence
Knee osteoarthritis600-1,200mg daily in 2-3 divided dosesStrong
Hip osteoarthritis600-1,200mg dailyModerate
OA with comorbid depression1,200mg dailyModerate
Full SAMe (S-Adenosyl Methionine) Guide

References

  1. (). Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. Journal of Family Practice.
  2. (). S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskeletal Disorders. DOI
  3. (). Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis. Journal of Korean Medical Science. DOI
  4. (). S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment (AHRQ).